Answers are grounded in this paper and cite their sources.
Reticulated platelets drive thromboinflammation in coronary artery disease via elevated GPVI-PI3K signaling, presenting a potential target for precision antiplatelet therapy.
Reticulated platelets (RPs) are prothrombotic in coronary artery disease, distinct drivers of thromboinflammation, and may be targets for precision antiplatelet therapy. RPs exhibit elevated GPVI-PI3K signaling that are attenuated by Glenzocimab and LY294002. Experimental techniques to evaluate platelet function include Fluorescence-Assisted Flow Sorting (FACS) and will require murine models in future for mechanistic insight.
No takes yet. Share an insight, caveat, or question.
Park et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: